Cargando…

PB2348: OUTCOME OF VERY ELDERLY DIFFUSE LARGE B CELL LYMPHOMA, SINGLE CENTER EXPERIENCE, RETROSPECTIVE ANALYSIS

Detalles Bibliográficos
Autores principales:	Kong, Jee Hyun, Jang, Jaeyeon, Kim, Yundeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429705/ http://dx.doi.org/10.1097/01.HS9.0000976112.96462.70

Ejemplares similares

PB2348: THE PATIENT’S PERSPECTIVE ON CLNICAL TRIALS: RESULTS FROM A REGIONAL SURVEY IN HAEMATOLOGICAL CENTERS IN ANTWERP
por: Heyrman, B., et al.
Publicado: (2022)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2361: DIFFUSE LARGE B-CELL LYMPHOMA IN THE ELDERLY: RETROSPECTIVE ANALYSIS FROM A SINGLE CANCER CENTER IN ALGIERS
por: Faiza, Talbi, et al.
Publicado: (2023)

PB2327: IS THERE ANY VALUE OF GERIATRIC INDICES IN DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY?
por: Dragčević, Dora, et al.
Publicado: (2023)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

PB2320: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONG THE ELDERLY: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, Elena, et al.
Publicado: (2023)

PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION
por: Yan-Li, L., et al.
Publicado: (2022)

PB2374: DIFFERENCES IN MUTATIONAL SIGNATURE OF DIFFUSE LARGE B-CELL LYMPHOMAS ACCORDING TO THE PRIMARY ORGAN
por: Koh, Hyun Hee, et al.
Publicado: (2023)

PB2354: DIFFUSE LARGE B CELL LYMPHOMA IN 65: DIAGNOSTIC, PROGNOSTIC, PROGRESSIVE AND THERAPEUTIC ASPECTS
por: Mlayah, Zaineb, et al.
Publicado: (2023)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP
por: Filonenko, K., et al.
Publicado: (2022)

PB2678: THE PROGNOSTIC SIGNIFICANCE OF CONTROLLING NUTRITIONAL STATUS AND SARCOPENIA IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Go, Se‑il, et al.
Publicado: (2023)

PB2143: CLINICAL CHARACTERISTICS AND PROGNOSTIC FEATURES OF 63 HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER REAL-WORLD STUDY IN CHINA
por: Wang, C., et al.
Publicado: (2022)

PB2108: PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
por: Liang, X., et al.
Publicado: (2022)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

PB2341: EARLY MORTALITY VARIABLES IN PATIENTS OLDER THAN 75 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Lakhwani, Sunil Lakhwani, et al.
Publicado: (2023)

PB2404: ASSOCIATION OF P14ARF EXPRESSION WITH THE RISK OF PROGRESSION AND DEATH IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Sarpova, Maria, et al.
Publicado: (2023)

PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY: Keywords: Lymphoma, Bone marrow involvement
por: Kim, Min-Sun, et al.
Publicado: (2023)

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE
por: Zhang, Y., et al.
Publicado: (2022)

PB2169: METHYLATION OF P53-RESPONSIVE ONCOSUPPRESSIVE MICRORNA GENES IN DIFFUSE LARGE B-CELL LYMPHOMA TUMOR TISSUE
por: Voropaeva, E., et al.
Publicado: (2022)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

PB2290: IMPACT OF RESOURCE AVAILABILITY ON OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA IN PAKISTAN: A DEVELOPING COUNTRY EXPERIENCE
por: Iftikhar, Raheel, et al.
Publicado: (2023)

PB2588: PREDICTIVE MODEL OF IN-HOSPITAL CASE FATALITY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA DEVELOPING CORONAVIRUS INFECTION
por: Polyakov, Yuri, et al.
Publicado: (2023)

PB2355: CORRELATION OF MYD88 AND TNFAIP3 MUTATIONS WITH CLINICO-HEMATOLOGICAL PROFILE IN DIFFUSE LARGE B CELL LYMPHOMA
por: Shaat, Rana, et al.
Publicado: (2023)

PB2322: MULTIPLE PRIMARY TUMORS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Sahakyan, Lusine, et al.
Publicado: (2023)

PB2103: CAN WE ACCURATELY PREDICT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA IN THE RITUXIMAB ERA? RETROSPECTIVE COMPARISON OF IPI, AAIPI, R-IPI AND NCCN-IPI
por: Chorão, P., et al.
Publicado: (2022)

PB2141: CLINICOPATHOLOGICAL FEATURES AND OUTCOME OF CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA AND THE SIGNIFICANCE OF CD5 EXPRESSION STRENGTH: 10-YEAR SINGLE CENTER EXPERIENCE
por: Vukovic, V., et al.
Publicado: (2022)

PB2150: RELATIONSHIP BETWEEN P16 AND P53 CO-EXPRESSION AND SURVIVAL IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, E., et al.
Publicado: (2022)

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5mld7j3ic9bacti3mgf0cd5nlf